INTRODUCTION
Isoniazid, the hydrazide of isonicotinic acid, was synthesized for the first time in 1912 by two Czech scientists, 1 but its powerful antituberculous activity was detected only in 1951, 2 and the discovery of isoniazid was a milestone in the chemotherapy of tuberculosis.
3 Its activity is excellent against species of the Mycobacterium tuberculosis complex (M. tuberculosis, Mycobacterium bovis, Mycobacterium bovis BCG and Mycobacterium africanum), but it shows no or very little activity against non-tuberculous mycobacteria. 4 The mode of action of isoniazid has been the subject of intensive studies, and beyond pleiotropic effects like the inhibition of protein and nucleic acid synthesis, 5,6 the most constant finding was the loss of acid-fastness of the tubercle bacilli probably as a result of the inhibition of the synthesis of mycolic acids, the long-chained, branched fatty acids found in the cell wall. As these are confined essentially to the mycobacteria they represent a selective target for antimycobacterial drugs. 7, 8 Another hypothesis on the mode of action of isoniazid, originating from the chemical structure of isoniazid which is very similar to that of nicotinamide, aimed at the metabolism of nicotinamide adenine dinucleotide (NAD) which is an important cofactor of many enzyme systems in the bacterial cell. 7, 9 It was observed that isoniazid induced an activation of the mycobacterial NADase, followed by a diminution of the intracellular NAD concentration which could explain the pleiotropic effects on the mycobacterial cell by isoniazid.
9 Nevertheless, this hypothesis did not allow an explanation of resistance to isoniazid, as the effects on NAD were identical in isoniazid susceptible and resistant strains of M. tuberculosis.
10

ISONIAZID AND THE CATALASE-PEROXIDASE ENZYME
In the 1960s, Krüger-Thiemer and Seydel proposed the model that intracellular isoniazid should be transformed into iso-nicotinic acid by the catalase-peroxidase system. The structure of iso-nicotinic acid is very similar to that of nicotinic acid which is an important precursor of NAD. Thus, the accumulation of iso-nicotinic acid could lead to the production of iso-NAD and its incorporation instead of NAD as a non-functional cofactor of multiple enzyme systems.
11 Youatt et al. observed at the end of the 1960s the formation of a pigment precursor by the oxidation of isoniazid in the presence of NAD. The accumulation of this precursor was attributed to the reaction of isoniazid or one of its metabolites (iso-nicotinic acid or 4-pyridylmethanol) with the catalase-peroxidase enzyme.
12,13 More recently, Shoeb et al. could demonstrate the production of free radicals, and thus the potentiation of isoniazid toxicity, by the interaction of isoniazid and the catalaseperoxidase enzyme.
14 Shortly after the introduction of isoniazid into the therapy of tuberculosis, resistant strains were isolated from patients treated by isoniazid monotherapy, and it was observed that some of the highly resistant strains had lost their catalase activity and showed attenuated virulence in the guinea pig model.
15
Forty years later, 1992, the relationship between isoniazid resistance and loss of catalase activity was explained by the identification of the katG gene, encoding the catalase-peroxidase enzyme KatG of M. tuberculosis which is indispensable for isoniazid susceptibility. 16 The KatG protein shows the typical structure of bacterial HPI catalase-peroxidases and is divided into two parts which
